The FDA's proposed plan to implement its Section 503B pre-dissemination review has received pharma industry criticism, not only for being time and cost intensive, but also for potentially being unconstitutional. Will pharma advertisers seek social media shelter?
Firefox recommends the PDF Plugin for Mac OS X for viewing PDF documents in your browser.
We can also show you Legal Updates using the Google Viewer; however, you will need to be logged into Google Docs to view them.
Please choose one of the above to proceed!
LOADING PDF: If there are any problems, click here to download the file.
Published In:
Products Liability Updates
DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.
© Sarah Lovequist, Litigation Management, Inc. | Attorney Advertising
